An evaluation of hydromethylthionine as a treatment option for Alzheimer’s disease

References

• Matthews KA, Xu W, Gaglioti AH, et al. Racial and ethnic estimates of Alzheimer’s disease and related dementias in the United States (2015–2060) in adults aged >/=65 years. Alzheimers Dement. 2019 Jan;15(1):17–24.
   PubMed Web of Science ®Google Scholar
• Hardy JA, Higgins GA. Alzheimer’s disease: the amyloid cascade hypothesis. Science. 1992 Apr 10;256(5054):184–185.
   PubMed Web of Science ®Google Scholar
• Šimić G, Babić Leko M, Wray S, et al. Tau protein hyperphosphorylation and aggregation in Alzheimer’s disease and other tauopathies, and possible neuroprotective strategies. Biomolecules. 2016;6(1):6.
   PubMed Web of Science ®Google Scholar
• Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer’s disease. Trends Pharmacol Sci. 1991 Oct;12(10):383–388.
   PubMed Web of Science ®Google Scholar
• Li C, Gotz J. Tau-based therapies in neurodegeneration: opportunities and challenges. Nat Rev Drug Discov. 2017 Dec;16(12):863–883.
   PubMed Web of Science ®Google Scholar
• Morris GP, Clark IA, Vissel B. Questions concerning the role of amyloid-beta in the definition, aetiology and diagnosis of Alzheimer’s disease. Acta Neuropathol. 2018 Nov;136(5):663–689.
   PubMed Web of Science ®Google Scholar
• Mullane K, Williams M. Alzheimer’s therapeutics: continued clinical failures question the validity of the amyloid hypothesis – but what lies beyond? Biochem Pharmacol. 2013 Feb 1;85(3):289–305.
   PubMed Web of Science ®Google Scholar
• Panza F, Lozupone M, Seripa D, et al. Amyloid-beta immunotherapy for alzheimer disease: is it now a long shot? Ann Neurol. 2019 Mar;85(3):303–315.
   PubMed Web of Science ®Google Scholar
• Cleveland DW, Hwo SY, Kirschner MW. Purification of tau, a microtubule-associated protein that induces assembly of microtubules from purified tubulin. J Mol Biol. 1977 Oct 25;116(2):207–225.
   PubMed Web of Science ®Google Scholar
• Goedert M, Wischik CM, Crowther RA, et al. Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: identification as the microtubule-associated protein tau. Proc Natl Acad Sci U S A. 1988 Jun;85(11):4051–4055.
   PubMed Web of Science ®Google Scholar
• Weingarten MD, Lockwood AH, Hwo SY, et al. A protein factor essential for microtubule assembly. Proc Natl Acad Sci U S A. 1975 May;72(5):1858–1862.
   PubMed Web of Science ®Google Scholar
• Cardenas-Aguayo Mdel C, Gomez-Virgilio L, DeRosa S, et al. The role of tau oligomers in the onset of Alzheimer’s disease neuropathology. ACS Chem Neurosci. 2014 Dec 17;5(12):1178–1191.
   PubMed Web of Science ®Google Scholar
• Gerson JE, Mudher A, Kayed R. Potential mechanisms and implications for the formation of tau oligomeric strains. Crit Rev Biochem Mol Biol. 2016 Nov/Dec;51(6):482–496.
   PubMed Web of Science ®Google Scholar
• Congdon EE, Sigurdsson EM. Tau-targeting therapies for Alzheimer disease. Nat Rev Neurol. 2018 Jul;14(7):399–415.
   PubMed Web of Science ®Google Scholar
• Panza F, Solfrizzi V, Seripa D, et al. Tau-centric targets and drugs in clinical development for the treatment of Alzheimer’s disease. Biomed Res Int. 2016;2016:3245935.
   PubMed Web of Science ®Google Scholar
• Wischik CM, Harrington CR, Storey JM. Tau-aggregation inhibitor therapy for Alzheimer’s disease. Biochem Pharmacol. 2014 Apr 15;88(4):529–539.
   PubMed Web of Science ®Google Scholar
• Khoury R, Patel K, Gold J, et al. Recent progress in the pharmacotherapy of Alzheimer’s disease. Drugs Aging. 2017 Nov;34(11):811–820.
   PubMed Web of Science ®Google Scholar
• Cooksey CJ. Quirks of dye nomenclature. 8. Methylene blue, azure and violet. Biotech Histochem. 2017;92(5):347–356.
   PubMed Web of Science ®Google Scholar
• PROVAYBLUE™ (me t hy l e ne bl ue) i n je c ti o n, f o r i nt r a v e no us us e. FDA package insert 2016. [cited 2020 Jan 4]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/204630s000lbl.pdf
   Google Scholar
• Ginimuge PR, Jyothi SD. Methylene blue: revisited. J Anaesthesiol Clin Pharmacol. 2010 Oct;26(4):517–520.
   PubMedGoogle Scholar
• Baddeley TC, McCaffrey J, Storey JM, et al. Complex disposition of methylthioninium redox forms determines efficacy in tau aggregation inhibitor therapy for Alzheimer’s disease. J Pharmacol Exp Ther. 2015 Jan;352(1):110–118.
   PubMed Web of Science ®Google Scholar
• Schelter BO, Shiells H, Baddeley TC, et al. Concentration-dependent activity of hydromethylthionine on cognitive decline and brain atrophy in mild to moderate Alzheimer’s disease. J Alzheimers Dis. 2019;72(3):931–946.
   PubMed Web of Science ®Google Scholar
• Al-Hilaly YK, Pollack SJ, Rickard JE, et al. Cysteine-independent inhibition of Alzheimer’s disease-like paired helical filament assembly by leuco-methylthioninium (LMT). J Mol Biol. 2018 Oct 19;430(21):4119–4131.
   PubMed Web of Science ®Google Scholar
• Methylene blue. U.S. national library of medicine. National Center for Biotechnology Information. [cited 2020 Jan 4]. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Methylene-blue
   Google Scholar
• Methylthioninium chloride dihydrate. National Center for Biotechnology Information.[cited 2020 Jan 4]. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Methylthioninium-chloride-dihydrate.
   Google Scholar
• Hydromethylthionine. KEGG DRUG database. [cited 2020 Jan 4]. Available from: https://www.genome.jp/dbget-bin/www_bget?dr:D11427
   Google Scholar
• Harrington CR, Storey JM, Clunas S, et al. Cellular models of aggregation-dependent template-directed proteolysis to characterize tau aggregation inhibitors for treatment of Alzheimer disease. J Biol Chem. 2015 Apr 24;290(17):10862–10875.
   PubMed Web of Science ®Google Scholar
• Melis V, Magbagbeolu M, Rickard JE, et al. Effects of oxidized and reduced forms of methylthioninium in two transgenic mouse tauopathy models. Behav Pharmacol. 2015 Jun;26(4):353–368.
   PubMed Web of Science ®Google Scholar
• Congdon EE, Wu JW, Myeku N, et al. Methylthioninium chloride (methylene blue) induces autophagy and attenuates tauopathy in vitro and in vivo. Autophagy. 2012 Apr;8(4):609–622.
   PubMed Web of Science ®Google Scholar
• Hochgrafe K, Sydow A, Matenia D, et al. Preventive methylene blue treatment preserves cognition in mice expressing full-length pro-aggregant human Tau. Acta Neuropathol Commun. 2015 May 10;3:25.
   PubMed Web of Science ®Google Scholar
• Akoury E, Pickhardt M, Gajda M, et al. Mechanistic basis of phenothiazine-driven inhibition of tau aggregation. Angew Chem Int Ed Engl. 2013 Mar 18;52(12):3511–3515.
   PubMed Web of Science ®Google Scholar
• Al-Hilaly YK, Pollack SJ, Vadukul DM, et al. Alzheimer’s disease-like paired helical filament assembly from truncated tau protein is independent of disulfide crosslinking. J Mol Biol. 2017 Nov 24;429(23):3650–3665.
   PubMed Web of Science ®Google Scholar
• Prasad KN, Cole WC, Prasad KC. Risk factors for Alzheimer’s disease: role of multiple antioxidants, non-steroidal anti-inflammatory and cholinergic agents alone or in combination in prevention and treatment. J Am Coll Nutr. 2002 Dec;21(6):506–522.
   PubMed Web of Science ®Google Scholar
• Stack C, Jainuddin S, Elipenahli C, et al. Methylene blue upregulates Nrf2/ARE genes and prevents tau-related neurotoxicity. Hum Mol Genet. 2014 Jul 15;23(14):3716–3732.
   PubMed Web of Science ®Google Scholar
• Peter C, Hongwan D, Kupfer A, et al. Pharmacokinetics and organ distribution of intravenous and oral methylene blue. Eur J Clin Pharmacol. 2000 Jun;56(3):247–250.
   PubMed Web of Science ®Google Scholar
• Lamont AS, Roberts MS, Holdsworth DG, et al. Relationship between methaemoglobin production and methylene blue plasma concentrations under general anaesthesia. Anaesth Intensive Care. 1986 Nov;14(4):360–364.
   PubMed Web of Science ®Google Scholar
• Wishart DS, Feunang YD, Guo AC, et al. DrugBank 5.0: a major update to the drug bank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074–d82.
   PubMed Web of Science ®Google Scholar
• DiSanto AR, Wagner JG. Pharmacokinetics of highly ionized drugs. II. Methylene blue–absorption, metabolism, and excretion in man and dog after oral administration. J Pharm Sci. 1972 Jul;61(7):1086–1090.
   PubMed Web of Science ®Google Scholar
• Wischik CM, Staff RT, Wischik DJ, et al. Tau aggregation inhibitor therapy: an exploratory phase 2 study in mild or moderate Alzheimer’s disease. J Alzheimers Dis. 2015;44(2):705–720.
   PubMed Web of Science ®Google Scholar
• TauRx Therapeutics Ltd. Safety study of TRx0237 in patients already taking medications for mild and moderate Alzheimer’s disease. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [Cited 2020 Jan 4]. Available from: https://clinicaltrials.gov/ct2/show/NCT01626391 NLM Identifier: NCT01626391.
   Google Scholar
• Gauthier S, Feldman HH, Schneider LS, et al. Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer’s disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial. Lancet. 2016 Dec 10;388(10062):2873–2884.
   PubMed Web of Science ®Google Scholar
• Wilcock GK, Gauthier S, Frisoni GB, et al. Potential of low dose leuco-methylthioninium bis(Hydromethanesulphonate) (LMTM) monotherapy for treatment of mild Alzheimer’s disease: cohort analysis as modified primary outcome in a phase III clinical Trial. J Alzheimers Dis. 2018;61(1):435–457.
   PubMed Web of Science ®Google Scholar
• TauRx Therapeutics Ltd. Safety and efficacy of TRx0237 in subjects with Alzheimer’s disease followed by open-label treatment. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [Cited 2020 Jan 4]. Available from: https://clinicaltrials.gov/ct2/show/NCT03446001. NLM Identifier: NCT03446001.
   Google Scholar
• Greenberg BD, Carrillo MC, Ryan JM, et al. Improving Alzheimer’s disease phase II clinical trials. Alzheimer’s Dementia. 2013;9(1):39–49.
   PubMed Web of Science ®Google Scholar
• Lexchin J. Sponsorship bias in clinical research. Int J Risk Saf Med. 2012;24(4):233–242.
   PubMedGoogle Scholar